Inhibrx Announces Merger and Spin-Off Agreements with Aventis
Market News

Inhibrx Announces Merger and Spin-Off Agreements with Aventis

Inhibrx (INBX) has released an update to notify the public and investors about an entry into a material definitive agreement.

On January 22, 2024, Inhibrx, Inc. entered into a Merger Agreement with Aventis Inc. and Art Acquisition Sub, Inc., which outlined that Inhibrx will merge and survive as a subsidiary of Aventis’s parent company, Sanofi. Concurrently, a Separation and Distribution Agreement was made with Ibex SpinCo, Inc. to handle the Pre-Closing Reorganization and distribute 92% of SpinCo’s shares to Inhibrx shareholders, while Inhibrx retains an 8% stake. Amendments to the Private Placement Warrants and Oxford Warrants were executed to clarify their treatment in the Merger and Spin-Off. The Merger and Spin-Off are anticipated to be taxable events for Inhibrx’s stockholders.

For further insights into INBX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyInhibrx prevails in trade secret case with I-Mab
TheFlyInhibrx management to meet virtually with Jefferies
TipRanks Auto-Generated NewsdeskInhibrx Biosciences Reveals Updated Corporate Presentation
Go Ad-Free with Our App